Cadila Healthcare Ltd is currently trading at Rs 465, down by Rs 13.65 or 2.85% from its previous closing of Rs 478.65 on the BSE.
Zydus today announced that the Mexico regulatory authority COFEPRIS (Federal Commission for the Protection Against Sanitary Risk), has granted marketing approval to commercialize Lipagly (Saroglitazar Magnesium) in Mexico for the treatment of Dyslipidemia in patients with diabetes mellitus type 2 and Hypertriglyceridemia in patients with diabetes mellitus type 2 not controlled by statins.
Elevated triglycerides and insulin resistance are two key components of the metabolic syndrome, which medical science believes are responsible for diseases like hypertriglyceridemia, diabetic dyslipidemia or Non-Alcoholic Steatohepatitis disease (NASH). Increased triglyceride accumulation in the liver can also lead to inflammation, fibrosis, cirrhosis and liver failure, a serious medical condition known as NAFLD or NASH. Additionally, Zydus is currently evaluating Saroglitazar in several clinical trials for treating liver conditions like NASH and Primary Biliary Cholangitis (PBC).
"Saroglitazar is an important scientific and medical breakthrough in our effort to develop medicines for patients suffering from hypertriglyceridemia and diabetic dyslipidemia", said Pankaj Patel, Chairman, Zydus Group, and added, "This approval of Saroglitazar in Mexico is a major milestone for the company."
Cadila Healthcare Ltd is currently trading at Rs 465, down by Rs 13.65 or 2.85% from its previous closing of Rs 478.65 on the BSE. The scrip opened at Rs 476 and has touched a high and low of Rs 478 and Rs 464.5 respectively.
(c) 2017India Infoline Ltd. All rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers